Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$118.64 USD

118.64
11,134,082

+0.35 (0.30%)

Updated Sep 18, 2024 04:00 PM ET

After-Market: $118.97 +0.33 (0.28%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Countdown to Merck (MRK) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.

AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View

AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.

AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 3.11% and 2.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Merck (MRK) Gains As Market Dips: What You Should Know

Merck (MRK) closed at $125.92 in the latest trading session, marking a +1.24% move from the prior day.

Sweta Killa headshot

What Lies in Store for Healthcare ETFs in Q2 Earnings?

The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.

Kinjel Shah headshot

Should You Buy, Sell or Hold Merck (MRK) Ahead of Q2 Earnings?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports second-quarter 2024 earnings.

Merck (MRK) Earnings Expected to Grow: Should You Buy?

Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (MRK) Stock Sinks As Market Gains: Here's Why

Merck (MRK) closed at $125.69 in the latest trading session, marking a -0.06% move from the prior day.

Elanco (ELAN) Stock Declines After Sale of Aqua Business

Elanco (ELAN) completes the sale of Aqua Business to Merck Animal Health for $1.3 billion to strengthen its financial flexibility and accelerate debt reduction.

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer

Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.

Kinjel Shah headshot

Merck (MRK) Up 17% YTD on Keytruda Strength: Should You Buy?

Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.

Sundeep Ganoria  headshot

Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?

Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.

Is MannKind (MNKD) Outperforming Other Medical Stocks This Year?

Here is how MannKind (MNKD) and Merck (MRK) have performed compared to their sector so far this year.

Kinjel Shah headshot

4 Large Drug Stocks to Watch as Innovation, M&A Pick Up

Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Pfizer (PFE) are worth retaining in one's portfolio.

Merck (MRK) Stock Moves 0.28%: What You Should Know

In the closing of the recent trading day, Merck (MRK) stood at $128.12, denoting a +0.28% change from the preceding trading day.

Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals

Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line head and neck squamous cell carcinoma patients.

The Zacks Analyst Blog Highlights Exxon Mobil, Merck & Co, Qualcomm and Armanino Foods of Distinction

are included in this Analyst Blog Exxon Mobil, Merck & Co, Qualcomm and Armanino Foods of Distinction

Santanu Roy  headshot

Top Research Reports for Exxon Mobil, Merck & Qualcomm

Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), Merck & Co., Inc. (MRK) and QUALCOMM Incorporated (QCOM), as well as two micro-cap stocks Armanino Foods of Distinction, Inc. (AMNF) and AMCON Distributing Company (DIT).

Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know

Merck (MRK) reachead $126.04 at the closing of the latest trading day, reflecting a +0.21% change compared to its last close.

Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence

Eli Lilly's (LLY) acquisition of Morphic (MORF) is set to expand its immunology pipeline by adding the latter's lead candidate, MORF-057, which is being developed for IBD conditions.

The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche

Eli Lilly, Sanofi Merck, AstraZeneca's and Roche are included in this Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD

Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.